Vertex Pharmaceuticals Incorporated (ETR:VX1)
Germany · Delayed Price · Currency is EUR 352.85
-6.20 (-1.73%)
Oct 10, 2025, 5:35 PM CET
Vertex Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
| 11,388 | 11,020 | 9,869 | 8,931 | 7,574 | 6,206 | Upgrade | |
Revenue Growth (YoY) | 10.16% | 11.66% | 10.51% | 17.91% | 22.06% | 49.08% | Upgrade |
Cost of Revenue | 1,587 | 1,531 | 1,262 | 1,080 | 904.2 | 736.3 | Upgrade |
Gross Profit | 9,802 | 9,490 | 8,607 | 7,850 | 6,670 | 5,469 | Upgrade |
Selling, General & Admin | 1,570 | 1,464 | 1,137 | 944.7 | 840.1 | 770.5 | Upgrade |
Research & Development | 3,957 | 8,259 | 3,690 | 2,656 | 3,051 | 1,830 | Upgrade |
Other Operating Expenses | 2.2 | -0.5 | -51.6 | -57.5 | -3.1 | 13.1 | Upgrade |
Operating Income | 3,924 | -232.9 | 3,832 | 4,307 | 2,782 | 2,856 | Upgrade |
Interest Income | 503.7 | 598.1 | 614.7 | 144.6 | 4.9 | 22.2 | Upgrade |
Interest Expense | -17 | -30.6 | -44.1 | -54.8 | -61.5 | -58.2 | Upgrade |
Other Non-Operating Income (Expense) | -36.2 | -86.1 | -22.8 | -164.8 | 4.9 | 296.6 | Upgrade |
Total Non-Operating Income (Expense) | 450.5 | 481.4 | 547.8 | -75 | -51.7 | 260.6 | Upgrade |
Pretax Income | 4,374 | 248.5 | 4,380 | 4,232 | 2,730 | 3,117 | Upgrade |
Provision for Income Taxes | 736.4 | 784.1 | 760.2 | 910.4 | 388.3 | 405.2 | Upgrade |
Net Income | 3,638 | -535.6 | 3,620 | 3,322 | 2,342 | 2,712 | Upgrade |
Net Income to Common | 3,638 | -535.6 | 3,620 | 3,322 | 2,342 | 2,712 | Upgrade |
Net Income Growth | - | - | 8.96% | 41.84% | -13.63% | 130.43% | Upgrade |
Shares Outstanding (Basic) | 257 | 258 | 258 | 256 | 258 | 260 | Upgrade |
Shares Outstanding (Diluted) | 259 | 258 | 261 | 259 | 260 | 263 | Upgrade |
Shares Change (YoY) | -0.38% | -1.00% | 0.54% | -0.31% | -1.33% | 1.04% | Upgrade |
EPS (Basic) | 14.12 | -2.08 | 14.05 | 12.97 | 9.09 | 10.44 | Upgrade |
EPS (Diluted) | 13.98 | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 | Upgrade |
EPS Growth | - | - | 8.35% | 42.29% | -12.44% | 128.16% | Upgrade |
Free Cash Flow | 3,500 | -790.3 | 3,337 | 3,925 | 2,409 | 2,994 | Upgrade |
Free Cash Flow Growth | - | - | -14.99% | 62.97% | -19.55% | 100.39% | Upgrade |
Free Cash Flow Per Share | 13.50 | -3.06 | 12.81 | 15.15 | 9.27 | 11.37 | Upgrade |
Gross Margin | 86.07% | 86.11% | 87.21% | 87.90% | 88.06% | 88.14% | Upgrade |
Operating Margin | 34.45% | -2.11% | 38.83% | 48.23% | 36.73% | 46.03% | Upgrade |
Profit Margin | 31.94% | -4.86% | 36.68% | 37.20% | 30.92% | 43.70% | Upgrade |
FCF Margin | 30.73% | -7.17% | 33.81% | 43.95% | 31.80% | 48.24% | Upgrade |
EBITDA | 4,123 | -25.7 | 4,013 | 4,456 | 2,908 | 2,966 | Upgrade |
EBITDA Margin | 36.21% | -0.23% | 40.66% | 49.89% | 38.39% | 47.79% | Upgrade |
EBIT | 3,924 | -232.9 | 3,832 | 4,307 | 2,782 | 2,856 | Upgrade |
EBIT Margin | 34.45% | -2.11% | 38.83% | 48.23% | 36.73% | 46.03% | Upgrade |
Effective Tax Rate | 16.84% | 315.53% | 17.36% | 21.51% | 14.22% | 13.00% | Upgrade |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.